About ProAxsis
ProAxsis is a Healthcare company based in Belfast (United Kingdom) founded in 2013 by Lorraine Martin and Brian Walker, and was acquired by NetScientific in October 2020. Single protease activity is detected and quantified using immunoassay. ProAxsis has raised $2.79 million across 6 funding rounds from investors including European Union, EMV Capital and AB Group. Its chief executive, as recorded, is David Ribeiro. ProAxsis offers products and services including NEATstik, ProteaseTag Active Proteinase 3 Immunoassay, and ProteaseTag Technology. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its legal entity is PROAXSIS LTD. Its competitors include Abingdon Health and Orbit Discovery; 2 of its 2 listed competitors have raised funding.
Company details
ProAxsis was founded in 2013 in Belfast, United Kingdom, within the biotechnology sector. ProteaseTags, an active neutrophil elastase immunoassay, have been developed to bind and quantify the activity of specific proteases in complex biological samples. Services provided include clinical research support, biomarker development, and academic collaborations, with operations focused on diagnostic and research applications in healthcare.
- Headquarters Belfast, United Kingdom
- Founders Lorraine Martin, Brian Walker
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website proaxsis.com
- Social LinkedIn X YouTube
- Acquired by NetScientific (Oct 2020)
- Legal Name Proaxsis Ltd
- Date of Incorporation 16 Aug, 2013
- Jurisdiction BELFAST, NORTHERN IRELAND
- Total Equity Funding$2.79M (USD)
in 6 rounds
- Latest Funding Round$298.56K (USD), Seed
Jul 2025
- InvestorsEuropean Union
& 3 more
- Acquired byNetScientific
(Oct 2020)
Products & Services of ProAxsis
ProAxsis offers a comprehensive portfolio of products and services, including NEATstik, ProteaseTag Active Proteinase 3 Immunoassay, and ProteaseTag Technology.
Detects active neutrophil elastase for respiratory disease diagnostics.
Assay for detecting active proteinase biomarkers in chronic conditions.
Enables protease detection in ELISA and lateral flow devices.
Apps and channels of ProAxsis
its YouTube channel ProAxsis YouTube channel has 3 subscribers and 1 videos.
Videos from ProAxsis
The most watched videos on ProAxsis's YouTube channel, ProAxsis YouTube channel (3 subscribers). Click a video to play it here.
More on ProAxsis YouTube channel .
Funding Insights of ProAxsis
ProAxsis has successfully raised a total of $2.79M across 6 strategic funding rounds. The most recent funding activity was a Seed round of $298.56 thousand completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.79M
- Total Rounds 6
- Last Round Seed — $298,558
- First Round $253,313
(Feb 2014)
- Investors Count 4
All 6 funding rounds of ProAxsis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $298,558 | Seed | – | – | – |
| Apr 2024 | $2.24M | Seed | – | – | |
| Feb 2023 | $599,780 | Debt – Conventional | – | – | |
| Mar 2015 | $54,250 | Grant | – | – | |
| Oct 2014 | $63,090 | Grant | – | – | |
| Feb 2014 | $253,313 | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in ProAxsis
ProAxsis has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, EMV Capital and AB Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Venture capital investments are made in deep tech and life sciences by EMV Capital. | 2013 | netscientific.net | London, United Kingdom | |
AB Group is engaged in managing retail construction and refurbishment projects. | abgroup.com | Reigate, United Kingdom | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for ProAxsis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ProAxsis
6 people are tracked at ProAxsis (3 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Lorraine Martin | Co-Founder | Leadership |
Brian Walker | Co-Founder | Leadership |
David Ribeiro | CEO | Leadership |
Matthew McCaffrey | Research And Development Scientist | Team |
Shiva Shahandeh | Lab Manager | Team |
Timothy Ferguson | R&d Scientist | Team |
Complete people profiles for ProAxsis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ProAxsis
4 dated milestones of ProAxsis across 12 years, from founding to its latest funding, stage changes and deals.
- Founded ProAxsis is founded.
- Funding First funding round of $253K.
- Exit Acquired by NetScientific.
- Funding Latest funding round, Seed, of $299K.
Competitors of ProAxsis
ProAxsis has 2 listed competitors in our database, 2 of them funded. They include Abingdon Health and Orbit Discovery.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abingdonhealth.com | 2008 | York, United Kingdom | $24.05M | 151 | Developer of immunoassays for diagnostic purposes | |
| orbitdiscovery.com | 2015 | Oxford, United Kingdom | $15.73M | 26 | Drug discovery platform developed using peptide display engine. |
Detailed competitors of ProAxsis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ProAxsis
The website of ProAxsis (proaxsis.com) receives about 1.9K visits a month.
- Monthly visits1.9K
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as ProAxsis (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Proaxsis
Complete news archive for ProAxsis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ProAxsis
ProAxsis was founded in 2013 and raised its 1st funding round 1 year after it was founded.
ProAxsis is headquartered in Belfast, United Kingdom. It is registered at Belfast, Northern Ireland, United Kingdom.
David Ribeiro is the CEO of ProAxsis, as recorded in our data.
ProAxsis is a funded company, having raised a total of $2.79M across 6 funding rounds to date. The company's 1st funding round was a Seed of $253.31K, raised on Feb 2014.
ProAxsis was founded in 2013 in Belfast, United Kingdom, within the biotechnology sector. ProteaseTags, an active neutrophil elastase immunoassay, have been developed to bind and quantify the activity of specific proteases in complex biological samples. Services provided include clinical research support, biomarker development, and academic collaborations, with operations focused on diagnostic and research applications in healthcare.
ProAxsis's top competitors include Abingdon Health and Orbit Discovery.
ProAxsis offers NEATstik, ProteaseTag Active Proteinase 3 Immunoassay, and ProteaseTag Technology.
ProAxsis has 4 investors. Key investors include European Union, EMV Capital, AB Group, and EIC Fund.
ProAxsis operates through Proaxsis Ltd.
Yes. ProAxsis was acquired by NetScientific in October 2020.